Pyxis Oncology, Inc.
NASDAQ: PYXS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Thomas Civik
- Employees
- 44
- Headquarters
- Boston, United States
- IPO year
- 2021
- Market cap
- $137.5M
- Website
- https://www.pyxisoncology.com
Loading PYXS…
Loading profile data…Frequently asked questions about PYXS
What does Pyxis Oncology, Inc. (PYXS) do?
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential effic...
Where does PYXS trade?
Pyxis Oncology, Inc. (PYXS) trades on the NASDAQ Global Select.
What sector is PYXS in?
Pyxis Oncology, Inc. (PYXS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Pyxis Oncology, Inc.?
Thomas Civik is the chief executive officer of Pyxis Oncology, Inc. (PYXS).
Where is Pyxis Oncology, Inc. headquartered?
Pyxis Oncology, Inc. is headquartered in United States.
Does PYXS pay a dividend?
Pyxis Oncology, Inc. (PYXS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PYXS go public?
Pyxis Oncology, Inc. (PYXS) completed its initial public offering in 2021.